S Aubrey Stoch

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant
    S Aubrey Stoch
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Cancer Chemother Pharmacol 67:1313-21. 2011
  2. ncbi Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies
    S A Stoch
    Merck Research Laboratories, Rahway, New Jersey, USA
    Clin Pharmacol Ther 86:175-82. 2009
  3. ncbi Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial
    S Aubrey Stoch
    Merck and Co, Inc, 126 E Lincoln Ave, Rahway, NJ 07065
    J Rheumatol 36:1705-14. 2009
  4. ncbi Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists
    S A Stoch
    Division of Bone and Mineral Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Clin Endocrinol Metab 86:2787-91. 2001
  5. ncbi Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm
    S A Stoch
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Clin Pharmacol 49:398-406. 2009
  6. ncbi Cathepsin K inhibitors: a novel target for osteoporosis therapy
    S A Stoch
    Department of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey, USA
    Clin Pharmacol Ther 83:172-6. 2008
  7. ncbi Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
    Rajesh Krishna
    Merck and Co, Inc, Whitehouse Station, NJ 07065 0900, USA
    Br J Clin Pharmacol 74:116-24. 2012
  8. ncbi Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?
    Evan J Friedman
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    J Clin Pharmacol 51:1561-70. 2011
  9. ncbi Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients
    Marc L Reitman
    Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065 0900, USA
    J Clin Pharmacol 52:1306-16. 2012
  10. ncbi Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist
    Carol Addy
    Merck Research Laboratories, Boston, MA 02115, USA
    J Clin Pharmacol 49:1228-38. 2009

Collaborators

Detail Information

Publications21

  1. ncbi Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant
    S Aubrey Stoch
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Cancer Chemother Pharmacol 67:1313-21. 2011
    ..Because glucocorticoids and the neurokinin-1 receptor antagonist aprepitant influence CYP3A4 activity, this study assessed whether aprepitant added to a 5-HT(3) antagonist and glucocorticoid would affect CYP3A4 induction...
  2. ncbi Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies
    S A Stoch
    Merck Research Laboratories, Rahway, New Jersey, USA
    Clin Pharmacol Ther 86:175-82. 2009
    ..ODN exhibits robust and sustained suppression of bone resorption biomarkers (CTx and NTx/Cr) at weekly doses > or = 25 mg and daily doses > or = 2.5 mg...
  3. ncbi Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial
    S Aubrey Stoch
    Merck and Co, Inc, 126 E Lincoln Ave, Rahway, NJ 07065
    J Rheumatol 36:1705-14. 2009
    ..We evaluated the efficacy and safety of once-weekly bisphosphonate therapy for prevention and treatment of bone loss in patients on glucocorticoid therapy...
  4. ncbi Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists
    S A Stoch
    Division of Bone and Mineral Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Clin Endocrinol Metab 86:2787-91. 2001
    ..In conclusion, men with prostate cancer receiving androgen deprivation therapy have a significant decrease in bone mass and increase in bone turnover, thus placing them at increased risk of fracture...
  5. ncbi Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm
    S A Stoch
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Clin Pharmacol 49:398-406. 2009
    ..17, 1.57) and (0.83, 1.23), respectively. These findings suggest that short-term drug-drug interaction studies can predict the magnitude of change in AUC as reliably as studies using longer duration treatments...
  6. ncbi Cathepsin K inhibitors: a novel target for osteoporosis therapy
    S A Stoch
    Department of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey, USA
    Clin Pharmacol Ther 83:172-6. 2008
    ..Cathepsin K inhibitors represent a novel target for developing agents to treat osteoporosis and other disorders characterized by increased bone resorption...
  7. ncbi Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
    Rajesh Krishna
    Merck and Co, Inc, Whitehouse Station, NJ 07065 0900, USA
    Br J Clin Pharmacol 74:116-24. 2012
    ..Thus, no dosage adjustment for warfarin is necessary when co-administered with anacetrapib...
  8. ncbi Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?
    Evan J Friedman
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    J Clin Pharmacol 51:1561-70. 2011
    ..In addition, the authors believe that a hepatic CYP3A kdeg of 0.03 h(-1) should be considered for future Simcyp studies...
  9. ncbi Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients
    Marc L Reitman
    Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065 0900, USA
    J Clin Pharmacol 52:1306-16. 2012
    ..Oral administration of MK-5046 achieves plasma concentrations that are projected to activate BRS-3 and therefore should be suitable for exploring its biological role in humans...
  10. ncbi Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist
    Carol Addy
    Merck Research Laboratories, Boston, MA 02115, USA
    J Clin Pharmacol 49:1228-38. 2009
    ..Coadministration of taranabant 0.5 mg, 1 mg, and 2 mg with phentermine was well tolerated with no pharmacokinetic interaction and did not result in meaningful changes in blood pressure or heart rate versus placebo...
  11. ncbi [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor
    H Donald Burns
    Imaging Research, Merck Research Laboratories, West Point, PA 19486, USA
    Proc Natl Acad Sci U S A 104:9800-5. 2007
    ..In addition, it allows demonstration of target engagement and noninvasive dose-occupancy studies to aid in dose selection for clinical trials of CB1R inverse agonists...
  12. ncbi Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease
    Carol Addy
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Clin Pharmacol 49:856-64. 2009
    ..The results of this study do not support ongoing clinical development of MK-0657 as a novel monotherapy for Parkinson's disease...
  13. ncbi Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
    M G Murphy
    Merck Research Laboratories, Building 5W, Sentry Rahway, NJ 07065, USA
    J Clin Endocrinol Metab 90:2022-8. 2005
    ..Furthermore, 200 mg L-000845704 bid provided efficacy at the hip sites. These data suggest that the alphaVbeta3 integrin antagonist L-000845704 could be developed as an effective therapeutic agent for osteoporosis...
  14. ncbi Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study
    Iain P Fraser
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Headache 52:625-35. 2012
    ..To evaluate the pharmacokinetic profile and tolerability of single doses of rizatriptan oral disintegrating tablets (ODTs) in pediatric migraineurs...
  15. ncbi Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects
    Rajesh Krishna
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    Biopharm Drug Dispos 32:525-9. 2011
    ..Thus, no dosage adjustment for digoxin is necessary when co-administered with anacetrapib...
  16. ncbi Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event
    Mark Stroh
    Department of Clinical Drug Metabolism, Merck Research Laboratories, Merck and Co, Inc, WP75B 100, 770 Sumneytown Pike, P O Box 4, West Point, Pennsylvania 19486 0004, USA
    AAPS J 11:99-108. 2009
    ..Though this paradigm has yet to be tested in the clinic, our model-based approach provided a common rational framework to more fully utilize the limited available information for advancing the program...
  17. ncbi The effects of simvastatin on the pharmacokinectics of sitagliptin
    Michael Cerra
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, UDA
    J Popul Ther Clin Pharmacol 19:e356-60. 2012
    ....
  18. ncbi Classification of osteoporosis and osteopenia in men is dependent on site-specific analysis
    S A Stoch
    Division of Bone and Mineral Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    J Clin Densitom 3:311-7. 2000
    ..We conclude depending on the number and selection of sites there is considerable variability in the classification and misclassification of osteoporosis and osteopenia in men...
  19. ncbi Transforming growth factor-alpha (TGF alpha) inhibition of parietal cell secretion: structural requirements for activity
    J R Goldenring
    Department of Surgery, Yale University School of Medicine, New Haven, CT 06510
    Regul Pept 43:37-47. 1993
    ..In addition, in contrast with previous investigations on the mitogenic action of TGF alpha, third loop fragments of TGF alpha retain the capacity to inhibit aminopyrine accumulation...
  20. ncbi Enrichment of rab11, a small GTP-binding protein, in gastric parietal cells
    J R Goldenring
    Department of Surgery, Yale University School of Medicine, New Haven, Connecticut
    Am J Physiol 267:G187-94. 1994
    ..These results suggest that rab11 is enriched in parietal cells and is associated with intracellular tubulovesicles...
  21. ncbi Identification of rab2 as a tubulovesicle-membrane-associated protein in rabbit gastric parietal cells
    L H Tang
    Department of Surgery, Yale University School of Medicine, New Haven, CT
    Biochem J 285:715-9. 1992
    ..The results of the present study provide strong evidence that parietal cells possess a rab2 protein which is tightly associated with tubulovesicle membranes...